Gestational Diabetes Market Research Report – Global Forecast till 2027

Gestational Diabetes Market Research Report, By Type (Type A1, Type A2), By Administration (Oral, Intravenous), By Treatment (Monitoring, Drug Treatment, Non-Pharmacological Treatment), By End User (Hospital, Retail Pharmacy) - Global Forecast till 2027

ID: MRFR/Pharma/3172-HCR | February 2021 | Region: Global | 90 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario:


Diabetes is a metabolic disorder in which the body glucose level is elevated. Gestational diabetes is a temporary or permanent form of diabetes in which the body does not produce adequate amounts of insulin to regulate sugar during pregnancy. It may also be called glucose intolerance or carbohydrate intolerance. According to the International Diabetes Federation in 2016, it was estimated that 420 million adult population is suffering from diabetes which is increasing at the rate of 8.4% and is expected to reach 625 million by 2040. According to the American Pregnancy Association, approximately 2-5% of pregnant women develop gestational diabetes; this number may increase to 7-9% of mothers who are more likely to have risk factors. Increasing prevalence of the gestational diabetic population is the major driving factor for the growth of the market. Moreover, increasing obese population, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the market. According to research, smoking increases the possibility of diabetes; more than 60% of the global population smokes, this has increased the risk of diabetes and contributed to the growth of the market. However, lack of awareness among people and cost issues may lead to restrain the growth of the market.


The global gestational diabetic market is expected to grow at a CAGR of 5.4% during forecast period. 


Intended Audience



  • Biotechnological institutes

  • Pharmaceutical companies

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Medical Research Laboratories 


Figure 1:- Global gestational diabetes market share, by region Global gestational diabetes market

    Annual reports, Press release, White paper, Company Presentation


 


Segmentation


The global gestational diabetes market is segmented on the basis of types, administration, treatment, and end users.


On the basis of types, the market is segmented into type A1, type A2 and others.


On the basis of administration, the market is categorised into oral, intravenous, and other.


On the basis of treatment, the market is segmented into monitoring, drug treatment, and non-pharmacological treatment. Monitoring is further segmented into urinary glucose testing, oral glucose tolerance test, and others. Drug treatment is subsegmented into insulin, sensitizers, SGLT-2 inhibitors, alpha-glucosidase inhibitors, and others


On the basis of end users, the market is segmented into hospital, retail pharmacy and other.


 


Regional Analysis


America dominates the global gestational diabetes market owing to large patient population. Apart from this, increasing number of obese people, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. According to the Centers for Disease Control and Prevention (2014), 73.5 million adults in the US were diagnosed with high cholesterol level. Increasing cholesterol level and smoking increases the possibility of causing diabetes. Additionally, increasing awareness among the people regarding different monitoring procedures and well-developed technology has also contributed to the growth of the market.


Europe is the second largest gestational diabetes market, which is followed by Asia Pacific. Huge smoking population, availability of funds for research, and government support for research & development will drive the market.


Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies, and increasing need for the better treatment.


On the other hand, the Middle East & Africa has the least share in the global gestational diabetes market due to presence of poor economy especially in Africa region. Majority of the market of this region is hold by Middle East due to well-developed healthcare sector and huge healthcare expenditure.


 


Research Methodology gestational diabetes market


Sources: WHO, annual reports, press release, white paper, and company presentation


 


 


Key players for global gestational diabetes market


Antares Pharma (US), INJEX Pharma AG (Germany), 3M (US), Eli Lilly (US), Biocon (US), Sunpharma (India), Sanofi (France), Novo Nordisk (Denmark), Abbott (US), AstraZeneca (UK), Novartis (Switzerland), Daiichi Sankyo (Japan), Boehringer Ingelheim (Germany), Merck & Co. (US), Pfizer (US), Akros Pharma (US), Amgen (US), Adocia (France), Peptron (South Korea), and Takeda (Japan).


 



TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Gestational Diabetes Market, by Type

6.1 Introduction

6.2 Type A1

Market Estimates & Forecast, 2020 – 2027

6.3 Type A2

Market Estimates & Forecast, 2020 – 2027

6.4 Others

Market Estimates & Forecast, 2020 – 2027

Chapter 7. Global Gestational Diabetes Market, by Administration

7.1 Introduction

7.2 Oral

Market Estimates & Forecast, 2020 – 2027

7.3 Intravenous

Market Estimates & Forecast, 2020 – 2027

7.4 Others

Market Estimates & Forecast, 2020 – 2027

Chapter 8. Global Gestational Diabetes Market, by Treatment

8.1 Introduction

8.2 Monitoring

Market Estimates & Forecast, 2020 – 2027

8.2.1 Urinary Glucose Testing

8.2.2 Oral Glucose Tolerance Test

8.2.3 Others

8.3 Drug Treatment

Market Estimates & Forecast, 2020 – 2027

8.3.1 Insulin

8.3.2 Sensitizers

8.3.3 SGLT-2 Inhibitors

8.3.4 Alpha-Glucosidase Inhibitors

8.3.5 Others

8.4 Non-Pharmacological Treatment

Market Estimates & Forecast, 2020 – 2027

Chapter 9 Global Gestational Diabetes Market, by End User

9.1 Introduction

9.2 Hospitals

9.2.1 Market Estimates & Forecast, 2020 – 2027

9.3 Retail Pharmacy

9.2.2 Market Estimates & Forecast, 2020 – 2027

9.4 Others

Chapter 10. Global Gestational Diabetes Market, by Region

10.1 Introduction

10.2 America

10.2.1 North America

10.2.1.1 US

10.2.1.1 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

Chapter 11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 Novartis AG

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 Antares Pharma

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Eli Lilly

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Biocon

12.4.1 Company Overview

12.4.2 Product/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Sanofi

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 Abbott

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 AstraZeneca

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Pharmaceutical industry

Chapter 14 Appendix

LIST OF TABLES

Table 1 Gestational Diabetes Industry Synopsis, 2020 – 2027

Table 2 Global Gestational Diabetes Market Estimates and Forecast, 2020 – 2027, (USD Million)

Table 3 Global Gestational Diabetes Market by Region, 2020 – 2027, (USD Million)

Table 4 Global Gestational Diabetes Market by Types, 2020 – 2027, (USD Million)

Table 5 Global Gestational Diabetes Market by Administration, 2020 – 2027, (USD Million)

Table 6 Global Gestational Diabetes Market by Treatment, 2020 – 2027, (USD Million)

Table 7 Global Gestational Diabetes Market by End Users, 2020 – 2027, (USD Million)

Table 8 North America Gestational Diabetes Market by Types, 2020 – 2027, (USD Million)

Table 9 North America Gestational Diabetes Market by Administration, 2020 – 2027, (USD Million)

Table 10 North America Gestational Diabetes Market by Treatment, 2020 – 2027, (USD Million)

Table 11 North America Gestational Diabetes Market by End Users, 2020 – 2027, (USD Million)

Table 12 US Market by Types, 2020 – 2027, (USD Million)

Table 13 US Gestational Diabetes Market by Administration, 2020 – 2027, (USD Million)

Table 14 US Gestational Diabetes Market by Treatment, 2020 – 2027, (USD Million)

Table 15 US Gestational Diabetes Market by End Users, 2020 – 2027, (USD Million)

Table 16 Canada Market by Types, 2020 – 2027, (USD Million)

Table 17 Canada Gestational Diabetes Market by Administration, 2020 – 2027, (USD Million)

Table 18 Canada Gestational Diabetes Market by Treatment, 2020 – 2027, (USD Million)

Table 19 Canada Gestational Diabetes Market by End Users, 2020 – 2027, (USD Million)

Table 20 South America Market by Types, 2020 – 2027, (USD Million)

Table 21 South America Gestational Diabetes Market by Administration, 2020 – 2027, (USD Million)

Table 22 South America Gestational Diabetes Market by Treatment, 2020 – 2027, (USD Million)

Table 23 South America Gestational Diabetes Market by End Users, 2020 – 2027, (USD Million)

Table 24 Europe Market by Types, 2020 – 2027, (USD Million)

Table 25 Europe Gestational Diabetes Market by Administration, 2020 – 2027, (USD Million)

Table 26 Europe Gestational Diabetes Market by Treatment, 2020 – 2027, (USD Million)

Table 27 Europe Gestational Diabetes Market by End Users, 2020 – 2027, (USD Million)

Table 28 Western Europe Market by Types, 2020 – 2027, (USD Million)

Table 29 Western Europe Gestational Diabetes Market by Administration, 2020 – 2027, (USD Million)

Table 30 Western Europe Gestational Diabetes Market by Treatment, 2020 – 2027, (USD Million)

Table 31 Western Europe Gestational Diabetes Market by End Users, 2020 – 2027, (USD Million)

Table 32 Eastern Europe Market by Types, 2020 – 2027, (USD Million)

Table 33 Eastern Europe Gestational Diabetes Market by Administration, 2020 – 2027, (USD Million)

Table 34 Eastern Europe Gestational Diabetes Market by Treatment, 2020 – 2027, (USD Million)

Table 35 Eastern Europe Gestational Diabetes Market by End Users, 2020 – 2027, (USD Million)

Table 36 Asia Pacific Market by Types, 2020 – 2027, (USD Million)

Table 37 Asia Pacific Gestational Diabetes Market by Administration, 2020 – 2027, (USD Million)

Table 38 Asia Pacific Gestational Diabetes Market by Treatment, 2020 – 2027, (USD Million)

Table 39 Asia Pacific Gestational Diabetes Market by End Users, 2020 – 2027, (USD Million)

Table 40 Middle East & Africa Market by Types, 2020 – 2027, (USD Million)

Table 41 Middle East & Africa Gestational Diabetes Market by Administration, 2020 – 2027, (USD Million)

Table 42 Middle East & Africa Gestational Diabetes Market by Treatment, 2020 – 2027, (USD Million)

Table 43 Middle East & Africa Gestational Diabetes Market by End Users, 2020 – 2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Gestational Diabetes Market

Figure 3 Segmentation Market Dynamics for Global Gestational Diabetes Market

Figure 4 Global Gestational Diabetes market Share, by Type 2020

Figure 5 Global Gestational Diabetes market Share, by Administration 2020

Figure 6 Global Gestational Diabetes market Share, by Treatment 2020

Figure 7 Global Gestational Diabetes Market Share, by End Users, 2020

Figure 8 Global Gestational Diabetes Market Share, by Region, 2020

Figure 9 North America Gestational Diabetes Market Share, by Country, 2020

Figure 10 Europe Gestational Diabetes Market Share, by Country, 2020

Figure 11 Asia Pacific Gestational Diabetes Market Share, by Country, 2020

Figure 12 Middle East & Africa Gestational Diabetes Market Share, by Country, 2020

Figure 13 Global Gestational Diabetes Market: Company Share Analysis, 2020 (%)

Figure 14 Novartis AG: Key Financials

Figure 15 Novartis AG: Segmental Revenue

Figure 16 Novartis AG: Geographical Revenue

Figure 17 Antares Pharma: Key Financials

Figure 18 Antares Pharma: Segmental Revenue

Figure 19 Antares Pharma: Geographical Revenue

Figure 20 Eli Lilly: Key Financials

Figure 21 Eli Lilly: Segmental Revenue

Figure 22 Eli Lilly: Geographical Revenue

Figure 23 Biocon: Key Financials

Figure 24 Biocon: Segmental Revenue

Figure 25 Biocon: Geographical Revenue

Figure 26 Sanof: Key Financials

Figure 27 Sanofi: Segmental Revenue

Figure 28 Sanofi: Geographical Revenue

Figure 29 Abbott: Key Financials

Figure 30 Abbott: Segmental Revenue

Figure 31 Abbott: Geographical Revenue

Figure 32 AstraZeneca: Key Financials

Figure 33 AstraZeneca: Segmental Revenue

Figure 34 AstraZeneca: Geographical Revenue